Quality control of iodine-131-labeled metaiodobenzylguanidine

Betül Taşdelen*, Erol Kam, Hizir Asliyuksek

*Bu çalışma için yazışmadan sorumlu yazar

Araştırma sonucu: ???type-name???Makalebilirkişi

3 Atıf (Scopus)

Özet

Aim/objectives/background: Iodine-131-m-iodobenzylguanidine ([ 131I]mIBG) is used worldwide for the diagnosis and therapy of neuroendocrine tumors, particularly adrenal medullae tumors. After the synthesis and preparation of a radioiodinated MIBG drug formulation, quality control testing to determine its radiochemical purity (RCP) should be performed. European Pharmacopoeia 8.0 requires that the quality control include a test for RCP for the determination of [131I]mIBG. Previously reported procedures using reversed-phase conditions require long retention times. Our system enables the separation of [131I]mIBG within a few minutes. The aim of this work was to carry out RCP testing for [131I]mIBG without any type of sample pretreatment. Methods: RCP testing for [131I]mIBG has been carried out using high-performance liquid chromatography and thin-layer chromatography methods. Results: A simple and rapid reversed-phase isocratic system enables the HPLC investigation of RCP testing for [ 131I]mIBG used for therapy within a few minutes. Conclusions: From the point of view of radiation protection, this method is safer, especially for therapeutic amounts of [131I]mIBG.

Orijinal dilİngilizce
Sayfa (başlangıç-bitiş)95-98
Sayfa sayısı4
DergiNuclear Medicine Communications
Hacim35
Basın numarası1
DOI'lar
Yayın durumuYayınlandı - Oca 2014
Harici olarak yayınlandıEvet

Parmak izi

Quality control of iodine-131-labeled metaiodobenzylguanidine' araştırma başlıklarına git. Birlikte benzersiz bir parmak izi oluştururlar.

Alıntı Yap